Assess whether RWE can replace or only supplement an RCT (805fd3)

Situation

The desk packet is CMC comparability package for a site change after a DSMB note on an imbalance that is not yet a signal. Clinical-development physician in an RWE group proposing a post-marketing study instead of a new RCT has to name RWE can replace or Only supplement an RCT for this Pharma & Life Sciences CMC and Development Pathways file.

Decision

Clinical-development physician in an RWE group proposing a post-marketing study instead of a new RCT must choose RWE can replace / Only supplement an RCT using CMC comparability package for a site change after a DSMB note on an imbalance that is not yet a signal.

Hypotheses to test

• CMC comparability package for a site change reads as RWE can replace once a DSMB note on an imbalance that is not yet a signal is lined up to the same Pharma & Life Sciences population.
• CMC comparability package for a site change is closer to Only supplement an RCT after a DSMB note on an imbalance that is not yet a signal; RWE can replace would over-claim this CMC and Development Pathways extract.
• A dual reading is still live in CMC comparability package for a site change for clinical-development physician in an RWE group proposing a post-marketing study instead of a new RCT.
• CMC comparability package for a site change is missing the fact clinical-development physician needs after a DSMB note on an imbalance that is not yet a signal; stop this Pharma & Life Sciences close.

Analysis required

• Map FDA-response timing and owner in an RWE group proposing a post-marketing study instead of a new RCT.
• Trace CMC, labeling, or pharmacovigilance facts in CMC comparability package for a site change after a DSMB note on an imbalance that is not yet a signal.
• Separate an isolated adverse event from a systemic quality issue.
• For this Pharma & Life Sciences CMC and Development Pathways file, read CMC comparability package for a site change against a DSMB note on an imbalance that is not yet a signal and write the one fact that would move RWE can replace or for clinical-development physician.

Recommendation

Choose RWE can replace / Only supplement an RCT on this Pharma & Life Sciences / CMC and Development Pathways packet (CMC comparability package for a site change after a DSMB note on an imbalance that is not yet a signal). Lead with the Pharma & Life Sciences option CMC comparability package for a site change can support after a DSMB note on an imbalance that is not yet a signal, then the two facts that force it, then the Monday action for clinical-development physician in an RWE group proposing a post-marketing study instead of a new RCT.